Royalty Pharma plc

Teva Pharmaceutical Industries – best known as a generic drug leader – has been focused on building an innovative drug portfolio, a key pillar of CEO Richard Francis’s “pivot to growth” strategy. The

Publicly traded biopharmaceutical companies have faced a rough year for fundraising in 2025 with the amount of money raised across all financing types down significantly from 2024 levels during the

Royalty Pharma has built a unique and valuable business model within the biopharma sector, buying royalty revenue streams in exchange for capital to finance drug development and commercialization. And

Biopharmaceutical companies raised just $13.1bn during the first quarter of 2025 – less than half of the $30.1bn raised in Q1 of 2024, the latest Financing Quarterly Statistics report from Biomedtra